Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy.
Immune checkpoint inhibitors
Immunotherapy
Inflammatory bowel disease
Malignancy
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
26 Feb 2022
26 Feb 2022
Historique:
received:
28
05
2021
revised:
19
07
2021
accepted:
11
01
2022
entrez:
23
3
2022
pubmed:
24
3
2022
medline:
24
3
2022
Statut:
ppublish
Résumé
Colitis is a known potential toxicity of immune checkpoint inhibitors (ICIs). Studies evaluating the risk of disease exacerbation following ICI treatment in patients with pre-existing inflammatory bowel disease (IBD) are limited. To assess the clinical characteristics of IBD patients treated with ICIs and determine prevalence of subsequent IBD exacerbations. We conducted a retrospective cohort study of all patients in the Stanford Research Repository database with pre-existing IBD who were exposed to ICIs. The prevalence of IBD exacerbation following ICI was 36.8% amongst 19 patients meeting inclusion criteria. Patients with exacerbations had more gastrointestinal-related hospitalizations (4 of 7) than patients without exacerbations (0 of 12; The prevalence of IBD exacerbations following ICI was higher than reported rates of ICI-induced colitis and diarrhea in the general population and was associated with hospitalization.
Sections du résumé
BACKGROUND
BACKGROUND
Colitis is a known potential toxicity of immune checkpoint inhibitors (ICIs). Studies evaluating the risk of disease exacerbation following ICI treatment in patients with pre-existing inflammatory bowel disease (IBD) are limited.
AIM
OBJECTIVE
To assess the clinical characteristics of IBD patients treated with ICIs and determine prevalence of subsequent IBD exacerbations.
METHODS
METHODS
We conducted a retrospective cohort study of all patients in the Stanford Research Repository database with pre-existing IBD who were exposed to ICIs.
RESULTS
RESULTS
The prevalence of IBD exacerbation following ICI was 36.8% amongst 19 patients meeting inclusion criteria. Patients with exacerbations had more gastrointestinal-related hospitalizations (4 of 7) than patients without exacerbations (0 of 12;
CONCLUSION
CONCLUSIONS
The prevalence of IBD exacerbations following ICI was higher than reported rates of ICI-induced colitis and diarrhea in the general population and was associated with hospitalization.
Identifiants
pubmed: 35317167
doi: 10.12998/wjcc.v10.i6.1787
pmc: PMC8891792
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1787-1794Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declare no conflicts of interest.
Références
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1285-1287.e1
pubmed: 32565289
Front Med (Lausanne). 2020 May 07;7:137
pubmed: 32457912
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
Arthritis Rheumatol. 2019 Dec;71(12):2100-2111
pubmed: 31379105
JCO Oncol Pract. 2020 Sep;16(9):e933-e942
pubmed: 32401685
Int Immunopharmacol. 2020 Oct;87:106770
pubmed: 32702598
Am J Gastroenterol. 2020 Feb;115(2):202-210
pubmed: 31922959
J Clin Oncol. 2020 Feb 20;38(6):576-583
pubmed: 31800340